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Abstract. The paper presents the approach for the building of consistent and applicable clinical 
decision support systems (CDSS) using a data-driven predictive model aimed to resolve a problem 
of low applicability and scalability of CDSS in real-world applications. The approach is based on the 
three-stage application of domain-specific and data-driven supportive procedures to integrate into 
clinical business-processes with higher trust and explainability of the prediction results and 
recommendations. Within the considered three stages, the regulatory policy, data-driven modes, and 
interpretation procedures are integrated to enable natural domain-specific interaction with decision-
makers with sequential narrowing of the intelligent decision support focus. The proposed 
methodology enables a higher level of automation, scalability, and semantic interpretability of CDSS. 
The approach was implemented in software solutions and tested within a case study in T2DM 
prediction, enabling to improve known clinical scales (such as FINDRISK), keeping the problem-
specific reasoning interface similar to existing applications. Such inheritance, together with the three-
stages approach, provide higher compatibility of the solution and leads to trust, valid, and explainable 
application of data-driven solution in real-world cases. 
Keywords. clinical decision support, predictive modeling, interpretable machine learning, 
personalized medicine, machine learning, diabetes mellitus  
1. Introduction 
Clinical decision support systems (CDSS) have a long history. Starting from the late 50s, they 
have been developed through several architectural approaches to the present days [1]. Still, having a 
proven capability of CDSS to improve clinical practice, the real-world application is limited due to 
multiple issues, including lack of trust, validity, scalability, etc. Clinical professionals who use 
CDSSes often over-rely on system suggestions - even if the suggestions are wrong [2]. On the other 
hand, attention to the suggestions produced by CDSS varies over time, eventually causing increasing 
in clinical decisions' quality, followed by certain decreasing due to lower attention to the suggestions 
[3]. At the same time, CDSSes cannot be entirely reliable due to the uncertainties and lack of data, 
and thus the correctness of their outputs may affect the quality of the decision-making [4]. Therefore, 
it is essential that clinical professionals who use CDSSes do not trust them blindly. This should be 
supported by the interpretability and interoperability of the decision support models [5]. Providing 
explanations could potentially mitigate misplaced trust in the system and over-reliance [6].  
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The recent development of machine learning and other artificial intelligence (AI) technologies 
[7] emphasizes both mentioned strengths and drawbacks of CDSSs. Moreover, relying on the 
available data, such technologies fall into the dependency on data and information uncertainty. 
Uncertainties originate in almost every step of a clinical decision-making process. Sources of 
uncertainties include patients who cannot describe their conditions, doctors and nurses cannot always 
interpret what they observe, laboratory results contain some degrees of error, and other sources of 
clinical data are inconsistent or not semantically interoperable.  
Systematic and thorough verification and validation of clinical decision support systems 
before they are released to general users is a crucial aspect of optimal software design [8]. Exclusion 
of this step may cause dangerous and potentially fatal consequences of relying on a clinical decision 
support system with uncertain outputs. The verification and validation of decision support systems 
employ various methods to detect errors in CDSSes using then in testing environments [9]. This 
includes, among others, validation of decision support models [10], [11], medical data [12], and 
clinical workflows [13]. Still, there is no commonly accepted approach or methodology for the 
verification and validation of CDSSes as a specific class of solutions. This leads to great achievements 
and limitations of intelligent technologies (see, e.g. [14] for discussion of possible issues of IBM 
Watson).  
Taking this into account, the work proposes a systematic, hybrid approach aimed towards the 
development of more trustable, valid, and explainable CDSSes using a combination of domain-
specific knowledge and intelligent technologies. A vital goal of the approach is to introduce best 
practices for building CDSSes that can be effectively adopted within the clinical pipelines, improve 
the quality of decision making, and keep the supportive power for a long period. 
2. Related works 
Barcelona Declaration for the Proper Development and Usage of Artificial Intelligence in 
Europe [19]  divides CDSSes into two fundamentally different types: knowledge-based and data-
driven.  Knowledge-based methodologies are well established but less able to exploit large volumes 
of data and often remain human-developed [20]–[25]. Validation of knowledge-based models can be 
performed by an expert review as they are usually based on the clinical guidelines. So, making sure 
that the rules are correctly defined is sufficient in most of the cases [17], [18]. 
Data-driven methods employ large amounts of empirical data processed with statistical 
machine learning methods to abstract patterns [26]–[34]. The need for validity and explainability is 
currently recognized as an essential problem to be solved by researchers. Validation of data-driven 
models often requires lengthy and expensive clinical evaluation, using metrics that are intuitive to 
clinicians and go beyond measures of technical accuracy and include quality of care and clinical 
effectiveness [35]. Implementation and adopting machine learning methods can be reasonably 
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straightforward. Still, the interpretation of the provided outcomes is sometimes complicated and 
indistinct due to the black-box nature of machine learning models [36]. 
The solution can be a combination of knowledge-based and data-driven models and methods. 
Even though every system should implement its own explanation module, which may vary based on 
the application domain and of the adopted methodologies and algorithms, we believe that, in general, 
the synergy between different knowledge types and AI methodologies can represent a promising 
strategy to deal with transparency and explainability issues. 
3. Three-stage clinical decision making 
3.1 Conceptual approach 
This section proposes basic structure and critical requirements in the proposed approach for 
CDSS implementation. The approach includes three main stages (see Fig. 1). The holistic way of the 
approach application is based on the tight interconnection of all three stages to support the integration 
of a CDSS into a clinical decision-making pipeline.  
 
Figure 1 – Three stages of the clinical decision support 
Stage 1 – Basic reasoning. This stage includes the digital implementation of grounded and 
known practices, policies, and rules implemented in conventional health care providing. An essential 
part of this stage is direct referencing to existing regulation policies. This type of referencing is 
necessary to a) get into the context of the existing medical practice; b) define a subset of relevant data 
and applicable knowledge for a specific disease, patient, case, etc.; c) provide reliable and trusted 
foundation for further reasoning.  
Stage 2 – Data-driven predictive modeling. The second stage includes the application of data-
driven models, including machine learning algorithms. The models should be applied within a context 
defined at the first stage of the approach. Key results of the stage are the extension of available 
information on a particular case. 
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Stage 3 – Explaining and detailed fact reasoning. This later stage of the application is essential 
due to several reasons. Firstly, the information set collected during the first two stages has high 
diversity. In the practical cases, different level of uncertainty, credibility in multitude observations, 
reasoning results, and model-based predictions is often critical for applicability. Secondly, 
explainability (e.g., with technologies like eXplainable Artificial Intelligence, XAI or Interpretable 
Machine Learning, IML) and domain integration (domain semantics) are vital for performing better 
human-computer interaction during clinical decision making. Finally, weighting and structuring of 
obtained results are needed to provide better recommendations. As a result, filtering, integration, and 
assessing procedures are implemented in this stage using XAI, heuristics, and explainable meta-
modeling. 
Meta-modeling procedures are an essential block responsible for structuring holistic three-stage 
decision support, which manages knowledge in various forms within three primary operations 
(forming a loop for building adaptive intelligent systems): 
− identification, training, and validation of basic predictive models and explaining meta-models 
using previous and current data; 
− updating and structuring domain (semantic) knowledge bases; 
− adapting and modification of official policies and recommendations. 
The last one should be mentioned separately. We consider this is an essential strategic operation 
where the results obtained using intelligent technologies can be introduced into the policies either 
implicitly during policy development, or explicitly considering intelligent technologies as 
recommended elements. We believe that the current development of AI may lead to such an explicit 
presence of intelligent technologies in the official policies soon. Still, to rich this level of automation, 
a certain level of validity, scalability, and trust should be reached. The proposed approach could be 
considered as a step towards this goal. 
3.2 Technological background 
The mentioned stages may be implemented in various ways employing different technologies 
for a solution. Table 1 summarizes the key features of the stages. The features reveal limitations of 
separate stages which can be overcome using the proposed approach. 
Table 1 – Summary of technological implementation in three stages 
 Stage 1 Stage 2 Stage 3 
Artifacts 
preparation  
Knowledge acquisition Data-driven models 
training 
Heuristics 
implementation, meta-
models training 
Intelligent 
technologies 
Rule-based inference, 
fuzzy logic 
Classification and 
regression models 
XAI/IML models, 
domain semantics  
Data 
processing 
Implicit, during 
knowledge acquisition 
Data filtering and 
integration, model 
Meta-model training 
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training (identification 
and updating) 
Data types - Patients and clinical 
cases 
Application of models, 
decision making 
Data 
integration 
- Yes No (unified data) 
Meta-
modeling 
Modification of 
knowledge base 
Model training tuning, 
surrogate modeling 
Meta-model training 
tuning, semantic 
knowledge update 
Context Clinical groups by 
official policies 
Sub-clinical 
(hierarchical) groups 
Problem domain 
Limitations Diversity in clinical 
groups, uncertainty 
Limited scalability, lack 
of systematic linage to 
domain 
Lack of systematic 
linage to domain 
Validation Evidence-based (during 
preparation), domain 
knowledge 
Cross-validation, 
statistics  
Simulation-based, meta-
model-based, 
experimental 
implementation 
Trust sources Official rules Validation, explanation Interpretation, linking to 
semantics 
Each stage has its own artifacts (models, knowledge bases, etc.), which are to be implemented 
using various intelligent technologies. This may include technologies mainly from AI or machine 
learning (ML) to support comprehensive decision making, data processing technologies (including 
technologies from the Big Data area), and meta-modeling procedures.  
An important part of a holistic decision support system within the proposed approach is to 
narrow the context during the stages. Commonly, clinical recommendations, policies, and other 
sources of knowledge in Stage 1 are relatively broad, covering key regulation of health care provision. 
Stage 2 is focused on working in sub-clinical groups by identification of classes, lowering diversity 
within a group, etc. Finally, Stage 3 deals with individual predictions, outliers, and explanations. 
Context control connects stages into a chain providing the right higher-level context for consecutive 
stages with the result of the previous stage(s) application. Building such a chain enhances a possible 
automatic application, scaling, and extension of the solutions. Moreover, building a context-
narrowing pipeline enables quantitative assessment and automation of value-based healthcare 
(VBHC) approach. VBHC considers diverse patient flow with requests for diverse care, even in a 
single clinical group. As a result, VBHC can work in all stages, while common evidence-based 
medicine is usually limited to Stage 1.  
Additionally, the interconnection of stages enables mutual support to overcome limitations such 
as a lack of validity and trust in particular stages as, in many cases, the available data and knowledge 
sources, validation procedures, are located in different stages. So, the holistic approach interconnects 
and enhance each stage within a general pipeline for decision support. 
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3.3 Clinical background 
From many systematic reviews on the application of data-driven clinical decision support, only 
a few have proved benefits on patient outcomes [37]–[39]. Nevertheless, many projects have operated 
too small samples or lasted too little to reveal clinically significant results related to patient outcomes 
[40], [41]. However, we can see substantial evidence that CDSS can certainly impact healthcare 
providers' efficiency with preventive care reminder solutions and drug prescription services being the 
most explicit examples [42]. The experience related to diagnostic CDSS can be explained that 
doctors, based on their clinical experience, can better come up with alternative diagnoses and rule 
them out than a CDSS [43]. In many cased, CDSSes are not able to detect and consider comorbid 
conditions, which is a big limitation to their use in real clinical settings. All these factors lower the 
impact of such CDSS in clinical practice.  
Furthermore, the data-driven diagnostic models often require input or import of a large amount 
of patient data to provide the result of the diagnostics. As long as this information is not available in 
the machine-readable form, e.g., in a semantically interoperable electronic medical record (EMR), 
clinicians have to enter missing data manually. The problem of manual data entry may make doctors 
give up or make mistakes, which can lead to the situation when CDSSes are not raising the efficiency, 
but require a lot of time and effort for operation [44], [45]. 
To provide efficient CDSS for the real clinical settings, developers should study how to increase 
CDSS content to consider multiple comorbidities simultaneously, how to provide and to estimate the 
effect of a CDSSs on clinical and organizational outcomes, and how CDSSs can be most effectively 
integrated into the workflow and deployed across diverse settings [43]. Clinical validation of CDSSes 
is a factor that can make their implementation successful. Provision of the evidence of clinical 
efficiency is a resource-consuming task that requires support from the sustainable validation 
methodology [46][47]. 
4. Experimental implementation and case study 
4.1 Platform implementation details 
To implement the proposed approach, a platform for model-based treatment support was 
developed. It includes both general instrumental solutions and basic methodological procedures for 
the application of the approach. Fig. 2 represents the general architecture of the platform, which 
includes three core blocks.  
Model training block includes a pipeline commonly implemented by data scientists. Still, the 
pipeline was extended in two aspects. Firstly, it explicitly follows the rule base constructed after the 
official guidelines, scales, recommendations, etc. to enable referring them within a context of data-
driven model application. The rules used in data selection, preprocessing, and filtering. Secondly, the 
automatic clinical pathway structuring and analysis [48] reveal actual clinical experience in diverse 
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patient flow even in a single disease. Such decomposition is furtherly used to train a set of data models 
for sub-clinical groups and provide a trained model with meta-information for their application. 
Within the implementation, the trained models were stored in *.pickle files following the predefined 
interface and implementing methods for checking model applicability and applying it.   
 
Figure 2 – General architecture 
Hosting the model was implemented using Flask framework and blackboard design pattern 
applying available models to the dictionary of patient's characteristics (blackboard). The model-
hosting procedures were implemented as a REST-full web-service accessible from various 
information systems (including mobile applications and medical information systems [49]. The 
blackboard pattern enables models from all three stages of the approach to be arranged using a unified 
interface. At the same time, the approach being implemented implicitly in the hosting algorithm apply 
the models sequentially by stages.  
Model-based support can be implemented in different medical information systems (MIS) (e.g., 
in an extension module of such system), personalized assisting solutions (including those running on 
mobile phones, and many others. Within our study, the proposed approach was used in the following 
implementations:  
− integrated module for MIS developed by PMT Online1 used for the support of chronic patient 
treatment [49]; 
− mobile application for daily support of chronic patients [50]; 
− web-applications for personalized, predictive modeling (see an example in Fig. 3). 
 
1 https://pmtonline.ru/ 
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Figure 3 – Experimental web-UI (left panel – synthetic patients (name, year of birth); right panel –  
results of the application of various DD models with urgency level encoded in labels' color) 
During our study, we've been mainly focused on chronic diseases as a target: arterial 
hypertension, diabetes mellitus, and chronic heart failure were selected as a running example. Each 
disease was considered within a scope of the proposed approach. At Stage 1, guidelines and scales 
applicable in the practice of physicians were considered and used to data preprocessing and baseline 
prediction. At Stage 2, predictive models were developed, trained, and applied based on prepared data 
and identified typical clinical pathways. Finally, at Stage 3, additional explanation and interpretation 
of models were applied for better clinical decision support. A summary with the references to further 
reading is provided in Table 2. References for Stage 1 were provided for official sources. References 
for Stages 2 and 3 were provided for a detailed description of our implementation of the models. 
Table 2 – Implemented pipelines in chronic disease treatment support (overview, references) 
Disease Stage 1 Stage 2 Stage 3 
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Diabetes 
mellitus 
FINDRISC, guidelines 
by ESC [51] 
Complications, 
compensation status [52] 
Personalized trajectories 
[52], [53], feature-based 
explanation 
Arterial 
hypertension 
SCORE [54], guidelines 
by ESC [55] 
Therapy effectiveness 
prediction [56] 
Controllability prediction 
[49] 
Chronic 
heart failure 
CHA2DS2-VASс [57] Stage prediction [58] Static and dynamic 
feature importance [58] 
4.2 Diabetes mellitus case study 
This section explains in detail a case study on the implementation of the proposed approach for 
a single disease, namely, type 2 diabetes mellitus (T2DM).  
4.2.1 Stage 1 – Basic reasoning 
Diabetes mellitus (DM) is one of the most common chronic diseases in the world. World 
Diabetes Federation experts predicted the number of patients with diabetes will increase by 1.5 times 
by 2030 and will reach 552 million people. The increase happens mainly due to patients with type 2 
diabetes (type 2 diabetes) [59]. For health care, this type of diabetes presents one of the highest 
priority problems, since this disease is associated with a large number of concomitant diseases, 
leading to early disability and increased cardiovascular risk. Studies have shown early detection of 
patients prone to insulin resistance and timely preventive measures reduce the risk of developing the 
disease in the future. Therefore, special methods are needed to identify the patients at risk. 
To date, several diabetic scoring algorithms are used in medical practice in various countries - 
AUSDRISK, DRS - Diabetes Risk Score, Omani Diabetes risk score, FINDRISK, Danish Diabetes 
Risk Score, and others [60]–[64]. The literature describes several approaches to treating diabetic 
scoring scales. A distinctive feature of the first approach is the inclusion of ethnicity characteristics 
in the set of attributes for calculation T2DM-risk. An example of this approach is the Australian type 
2 diabetes risk assessment tool (AUSDRISK) scale. Also, this scale includes signs of smoking, age, 
gender. The second approach is to create a model for one ethnic population. For example, the Omani 
Diabetes risk score was created to identify high risk among Omani Arabs. The scale showed good 
results for its population, but probably a decrease in the prognosis quality for other populations. The 
third approach to building scales is based on including only those predictors that can be identified 
using the survey. This approach includes the Danish Diabetes Risk Score. The method includes age 
(30-60), gender, body mass index, the presence of arterial hypertension, physical activity, and genetic 
burden for diabetes. This is a high-quality method. However, it predicts the presence of diabetes at 
the time of measurement. It is impossible to assess the diabetes mellitus risk for future long-time-
interval. 
One of the most common in medical practice is the Finnish FINDRISK scale questionnaire. 
This questionnaire is used in medical practice in Russia. It was validated in the Russian population 
and showed good results [65]. This questionnaire was also tested on populations of other countries 
and where it also showed the high quality of the prediction [66], [67]. However, this method assesses 
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a risk over the next ten years. Risk assessment for a shorter time interval will allow better planning 
of preventive events. 
Therefore, it is necessary to create a new scale of high quality and a relatively small interval for 
predicting. We selected features for calculation T2DM-risk based on the scales mentioned above, 
studies of features that influence the risk of developing diabetes [63], [68]–[73], current clinical 
guidelines [74] and expert opinion of endocrinologists from the Almazov National Medical Research 
Center2 (one of the leading cardiological centers in Russia). We will consider the advantages of the 
above scales and try to deal with the shortcomings. 
4.2.2 Stage 2 - Data-driven predictive modeling 
The study included 4,597 patients, 2,534 men, and 2,063 women. Patients were divided into 
two subgroups: the first subgroup includes 90% of patients who did not show signs of insulin 
resistance for the next five years, the second group includes 10% of patients who revealed chronic 
diabetes mellitus of 2 types after the next five years of observation (after measurements). All 
participants were treated at the Almazov National Medical Research Center in 2000-2019. 
Criteria for patient entry into the study: 
− Men and women without prediabetes and diabetes of any type and form (including gestational 
diabetes). 
− Age from 18 to 100 years. 
− The observation period of at least five years 
− Lack of pre-diabetic and diabetic measurements of glucose and glycosylated hemoglobin at the 
time of start observation 
To develop a data-driven predictive model, a selection of machine learning models was used 
considering the following models: K-Neighbors Classifier, Random Forest Classifier, Logistic 
Regression, SVC, XGB Classifier. Gaussian NB, Bernoulli NB, Multinomial NB. Parameters were 
selected using the cross-validation grid-search method. The final quality was checked on a test sample 
– data that didn't use in model training. Feature engineering was sequentially reducing the initial set 
of features and checking changes in the model's quality. 
As a result, we obtained a model for assessing the risk of type 2 diabetes over the next five 
years. 
Characteristics of the final model: 
− Required software - Python 3.6 
− Input - a vector of 6 medical indicators influencing the risk of AF 
− Output - the probability of developing T2DM within the next five years from the moment of 
the last measurement 
 
2 http://www.almazovcentre.ru/?lang=en 
11 
− Calculation algorithm - Gradient boosting over decision trees trained on precedents 
− Model accuracy - Accuracy: 70% on the test-samples (Accuracy: 88% on the training samples). 
4.2.3 Stage 3 - Explaining and detailed fact reasoning. 
The model was interpreted using two methods - Shapley Additive explanation (SHAP) and 
Partial Dependence Plots (PD-graphics). The SHAP method [75] splits the predictions into parts to 
identify the contribution to the prediction value from a particular attribute. The method is based on 
the Shapley Vector, a principle used in game theory to determine how much each player in a joint 
game contributes to its successful outcome. SHAP - values demonstrate how a particular feature 
contributed to the prediction (compared to prediction with some "basic" value of this trait). Table 3 
provides a list of abbreviations for Fig. 4. 
 
Figure 4 – SHAP chart for the model 
Table 3 – Feature's top 5 by the effect on the prediction. 
Abbreviations bmi mean_dbp mean_sbp bsa age 
Decryption Body mass 
index 
Average diastolic 
pressure 
Average Systolic 
pressure 
Body mass 
area 
Age 
As an example of the model's interpretation, let's look at SHAP – values for the top 3 most 
influential features. The features of body mass index at medium and high values increase the 
probability of developing AF by an average of 0.4. The mean DBP increases the probability of AF 
development by an average of 0.2 at high and medium pressure values and decreases by an average 
of 1.2 at low values. The body surface area contributes to prediction, increased risk only at high 
values, with average values the average contribution is close to 0, low values reduce the risk. 
We interpret the predictive model using Partial Dependence Plots. When constructing this 
graph, a variable is selected, and its value is continuously changing, while a prediction change is 
observed and recorded. Fig. 5 and 6 show graphs of the feature's influence on the predictions. 
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Figure 5 – PD-graph for the features of mean diastolic pressure 
 
Figure 6 – PD-graph for the features of body mass index 
The graphs show that the increase of features values influence on the predicted probability of 
developing T2DM. With SBP from 80 and BMI from 34, a further increase in the values of symptoms 
does not make an additional contribution to the variable. 
Let us compare the developed method with the most widely applicable method in medical 
practice - the FINDRISK scale. 
Characteristics of the scale: 
− Input - a vector of 8 medical indicators identified during the survey 
− Output - the probability of developing diabetes within ten years 
− Calculation Algorithm - Logistic regression trained on precedents 
− Model accuracy - Sensitivity 76.0%, specificity 60.2% for validation in the Siberian 
population (9360 people aged 45–69 years)[65]. 
Compared with this scale, the developed model works on fewer features (6 and 8). The model 
does not require sophisticated medical tests. With the similar quality of a prediction (sensitivity 76.0% 
and specificity 60.2% versus sensitivity 82.0% and specificity 62%), the lead time of the model is 
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higher (5 years against 10). Therefore, the method is interpretable and scalable, and the model can be 
used to assess the risk of T2DM. 
People with T2DM are often asymptomatic until complications develop. For this reason, T2DM 
may remain undetected for many years. Moreover, during the so-called pre-diabetic stage, when 
people have either impaired glucose tolerance or impaired fasting glucose, damage to blood vessels 
and nerves may already be underway [76]. Thus, the detection of individuals with prediabetes and 
undiagnosed T2DM is an important approach to prevent or delay the development of T2DM or its 
complications. To date, a lot of prediction methods have been developed to identify individuals with 
unknown T2DM or those with a high risk of T2DM development. Among all predictive modeling 
approaches, machine learning methods often achieve the highest prediction accuracy. Still, most 
machine learning models do not explain their prediction result, witch precluding their widespread use 
in healthcare [77]. As was reported in a systematic review in 2013, of the 65 non-invasive diabetes 
risk assessment tools available worldwide, only ten have reported on their use as a screening tool 
[78]. Findings from this review suggested that diabetes risk assessment tools were not widely used in 
practice. Barriers for healthcare practitioners to implement diabetes risk assessment tools were their 
attitudes toward the tools, impracticality to use the tools, and lack of reimbursement and regulatory 
support. [78] Also, considering differences in ethnic specificity and influencing factors in different 
regions, the majority of prediction models may not be readily applicable to all people worldwide. 
Prediction tools always need to be validated for each population before implementation [79].  
Consequently, the machine learning risk prediction system for T2DM, which is interpretable, 
easy to use, and meet the characteristics of the Russian population, is of current interest. 
Developed in this study model predicts the probability of T2DM development in the next five 
years, has reasonable accuracy, sensitivity, and specificity (70,0%, 76,0%, and 60,2%, respectively), 
is non-invasive and simple to use, includes only six variables (age, weight, body surface area, body 
mass index, mean systolic and diastolic blood pressure). These six variables are easy to obtain in 
clinical practice. Commonly, electronic patient records contain complete information required for this 
prediction tool, so it can be used to assess an individual's risk without direct face-to-face interaction.  
Thus, this model could be implemented for detecting individuals with a high risk of T2DM at the 
population level. However, such variables as blood pressure and body mass index may require an 
assessment by healthcare providers, so this model is hard may use as a self-administered (by patients) 
tool. Another limitation of the model is the fact that all patients included in the study were from one 
medical center. The model's accuracy may change when tested in different cohorts.  
For this reason, the tool needs to be tested and validated in other studies. Concerning the 
interpretability of the model, it is provided with clear, easy to understand plots, providing basic 
explanations of how the model works. From these plots, it becomes clear, how much a particular 
14 
factor contributed to the prediction at a particular value (SHAP plot) and at what value of the factor 
the highest prognostic capability is achieved (Partial Dependence Plots).  
In summary, developed in this study T2DM prediction model can be proposed to estimate the 
risk of T2DM in routing clinical practice after testing and validation on other samples. Based on the 
results of T2DM risk assessment by this tool following recommendations can be made: further 
screening (invasive blood glucose tests such as fasting plasma glucose levels or oral glucose tolerance 
tests) for those with high risk, lifestyle modification to prevent diabetes in the long- term for those 
with moderate risk. 
5. Discussion 
We have applied the proposed approach to the analysis and prediction of T2DM, where multiple 
scales are used in clinical practice [60]–[64]. The approach was elaborated through all three stages, 
and the results of data-driven predictive modeling were interpreted with both quantitative and 
structural comparison to the FINDRISK scale. This enabled a conceptual loop over all three stages 
and provided the following functionality: 
1) The three-stage approach enables validation of data-driven models in comparison to existing 
(trustable, manually checked, and widely applied in practice) scoring algorithms. This 
validation extends a common data-driven modeling pipeline with additional capabilities to 
assess the quantitative performance of the models (comparing to the scoring algorithm) and 
their structure (feature engineering compared to the feature selection in the scoring algorithm). 
2) The data-driven procedures mapped onto a similar interface as the existing scoring algorithm 
enables natural extension and modification of the algorithm based on its application results 
during the improvement cycle. This methodology provides a hybrid manual scoring vs. data-
driven concurrency environment where continuous improvement could be available through 
modification of knowledge in Stage 1. 
3) Furtherly, the implemented loop could be considered as the co-evolution process of the whole 
three-stage pipeline. It can improve overall performance and functionality, together with 
integrability and interpretability of the existing clinical business processes (BPs). Conceptual 
integration of all stages provides a human-understandable interface for decision support 
systems that can naturally work in practice. 
The proposed approach can be applied in a wide variety of contexts. Moreover, the approach 
furtherly could be translated into multiple areas where legal regulation is combined with a large 
amount of data available for data-driven predictive modeling. Several examples of such areas could 
include law, education, human resource management, and many others. At the same time, the 
approach may support revealing and elaboration of contradictions between formal regulation 
(considered as an ideal situation) and practice (exposed within the available real-world data). Here 
the contradiction may be discovered both on the level of diversity description (while comparing and 
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integration of Stages 1 and 2) and in real-word cases deviating from regulatory rules (while comparing 
and integration of Stages 1 and 3). Both may lead to the update of the Stage 1 rules, e.g., reworking 
official recommendation. Furthermore, we believe that with a certain level of trust achieved by data-
driven models, such models could be explicitly included in the official rules providing an enhanced 
level of automation and intelligent support of operational activity in corresponding areas. 
One of the possible directions of the development is focusing on the real-world behavior of 
agents, including decision-makers (physicians), clients (patients), and others. For instance, the 
extension of the decision beyond simple utility expectations with behavioral or information-
processing approaches became one of the most recent directions of the research [80]. The proposed 
approach, combined with appropriate models, enables discovery and interpretation of real-world 
patterns in expert practice to both enhance Stage 1 rules and support the experts with tighter 
integration into existing BPs.  
The issue of integration of the decision support functionality to the BPs is quite crucial due to 
several circumstances. Firstly, the existing BPs usually follow the Stage 1 rules as it is prescribed to 
the practitioners to work in a predefined way. The modification of such processes should consider 
limitations to provide proper and useful support. Secondly, any modifications should be applied to 
the existing BPs "as is" considering the human-centered activity of practitioners (not too ideal BPs). 
Third, the modification of BP should consider all types of the system's elements, namely, agents, IT 
solutions, resources, facilities, etc. Moreover, the DSS (and CDSS in particular) used to be an element 
of the IT sub-system. Therefore, good decision support should consider peculiarities of human-
computer interaction [3] and adaptation of support during the practice where both DSS and BP are 
co-evolving to some stable state. 
6. Conclusion 
In this paper, we have proposed a systematic, hybrid approach for the more trustable, valid, 
and interpretable CDSS using a combination of domain-specific knowledge and intelligent 
technologies. The approach introduces best practices for building CDSS that can be effectively 
adopted within the clinical pipelines, improve the quality of decision making, and keep their 
supportive efficiency for a long period. 
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